Bioventus Inc.

NasdaqGS:BVS Stock Report

Market Cap: US$515.7m

Bioventus Future Growth

Future criteria checks 3/6

Bioventus is forecast to grow earnings and revenue by 60% and 6.3% per annum respectively while EPS is expected to grow by 56.2% per annum.

Key information

60.0%

Earnings growth rate

56.19%

EPS growth rate

Medical Equipment earnings growth13.0%
Revenue growth rate6.3%
Future return on equityn/a
Analyst coverage

Low

Last updated17 Dec 2025

Recent future growth updates

Bioventus Inc. Just Recorded A 154% EPS Beat: Here's What Analysts Are Forecasting Next

Aug 09
Bioventus Inc. Just Recorded A 154% EPS Beat: Here's What Analysts Are Forecasting Next

Recent updates

Bioventus: A New Start

Dec 02

Bioventus (NASDAQ:BVS) Seems To Use Debt Quite Sensibly

Nov 26
Bioventus (NASDAQ:BVS) Seems To Use Debt Quite Sensibly

We Think Bioventus' (NASDAQ:BVS) Robust Earnings Are Conservative

Aug 14
We Think Bioventus' (NASDAQ:BVS) Robust Earnings Are Conservative

Bioventus Inc. Just Recorded A 154% EPS Beat: Here's What Analysts Are Forecasting Next

Aug 09
Bioventus Inc. Just Recorded A 154% EPS Beat: Here's What Analysts Are Forecasting Next
User avatar

Cost Effective Therapies And Regenerative Medicine Will Transform Global Markets

Accelerated adoption of minimally invasive therapies and portfolio expansion in regenerative medicine are driving higher margins and capturing increased demand from demographic trends.

Is Bioventus (NASDAQ:BVS) Using Too Much Debt?

May 07
Is Bioventus (NASDAQ:BVS) Using Too Much Debt?

Investors Aren't Buying Bioventus Inc.'s (NASDAQ:BVS) Revenues

Mar 08
Investors Aren't Buying Bioventus Inc.'s (NASDAQ:BVS) Revenues

Bioventus: Amply Rewarded For Recent Progress

Jan 05

Healing Numbers, Hurting Valuation: Bioventus' Mixed Bag In Q2 2024

Aug 12

Bioventus: Bullish On Path To Profitability

Jan 24

Earnings and Revenue Growth Forecasts

NasdaqGS:BVS - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20276464977813
12/31/20266073079833
12/31/20255671867703
9/27/2025564105356N/A
6/28/202556423436N/A
3/29/2025568-312425N/A
12/31/2024573-343739N/A
9/28/2024555-422830N/A
6/29/2024537-44811N/A
3/30/2024523-2227N/A
12/31/2023512-97815N/A
9/30/2023503-104010N/A
7/1/2023511-169818N/A
4/1/2023514-173-110N/A
12/31/2022512-104-25-14N/A
10/1/2022517-91-15-6N/A
7/2/2022497-19-46N/A
4/2/2022466-161120N/A
12/31/2021431-5923N/A
10/2/2021399-32935N/A
7/3/202137664046N/A
4/3/202132443136N/A
12/31/2020321165572N/A
9/26/2020320167167N/A
6/27/2020316126258N/A
3/28/2020339155554N/A
12/31/201934093841N/A
12/31/2018319-1N/A45N/A
4/2/2016266-23N/A25N/A
12/31/2015254-38N/A19N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BVS's forecast earnings growth (60% per year) is above the savings rate (3.3%).

Earnings vs Market: BVS's earnings (60% per year) are forecast to grow faster than the US market (16.1% per year).

High Growth Earnings: BVS's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: BVS's revenue (6.3% per year) is forecast to grow slower than the US market (10.5% per year).

High Growth Revenue: BVS's revenue (6.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if BVS's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/14 07:33
End of Day Share Price 2026/01/14 00:00
Earnings2025/09/27
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bioventus Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kyle RoseCanaccord Genuity
Caitlin CroninCanaccord Genuity
William PlovanicCanaccord Genuity